Duvortuxizumab

Duvortuxizumab (INN[1]) is a chimeric/humanized monoclonal antibody designed for the treatment of B-cell malignancies.[2]

Duvortuxizumab
Monoclonal antibody
TypeSingle-chain variable fragment
SourceChimeric/humanized hybrid (mouse/human)
TargetCD19
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC4850H7485N1305O1487S35
Molar mass108989.98 g·mol−1

This drug was developed by Janssen Global Services.[3]

References

  1. World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 116" (PDF). WHO Drug Information. 30 (4).
  2. Izhak L, Cullen DE, Elgawly M, Luistro L, Johnson S, Bald J, Sasser AK, Balasubramanian S (July 2017). "Potent antitumor activity of duvortuxizumab, a CD19 x CD3 DART® molecule, in lymphoma models". Cancer Research. doi:10.1158/1538-7445.AM2017-3636.
  3. Statement On A Nonproprietary Name Adopted By The USAN Council - Duvortuxizumab, American Medical Association.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.